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Abstract
Colorectal cancer (CRC) accounts for ~9% of all cancers in the Veteran population, a fact which has focused a great deal of
the attention of the VA’s research and development efforts. A field-based meeting of CRC experts was convened to discuss
both challenges and opportunities in precision medicine for CRC. This group, designated as the VA Colorectal Cancer Cellgenomics Consortium (VA4C), discussed advances in CRC biology, biomarkers, and imaging for early detection and prevention. There was also a discussion of precision treatment involving fluorescence-guided surgery, targeted chemotherapies and
immunotherapies, and personalized cancer treatment approaches. The overarching goal was to identify modalities that might
ultimately lead to personalized cancer diagnosis and treatment. This review summarizes the findings of this VA field-based
meeting, in which much of the current knowledge on CRC prescreening and treatment was discussed. It was concluded that
there is a need and an opportunity to identify new targets for both the prevention of CRC and the development of effective
therapies for advanced disease. Also, developing methods integrating genomic testing with tumoroid-based clinical drug
response might lead to more accurate diagnosis and prognostication and more effective personalized treatment of CRC.
Keywords Biomarkers · Cancer stem cells · Clinical drug response · Colorectal cancer · FiSS · Genomic testing · Next
generation sequencing · Precision Oncology Program (POP) · Tumoroids

Introduction
Colorectal cancer (CRC) is the second most common cause
of cancer-related deaths in the USA with an estimated 5%
lifetime risk [1]. Another 3% of individuals diagnosed with
CRC have a high-risk hereditary cancer syndrome such as
Lynch syndrome. In recent years, a major emphasis has been
placed on screening of conventional adenomatous and serrated polyps with the intention of removing them prior to
their progression to CRC. The serrated polyp has been recognized as a progenitor of 15–30% of all CRCs. Technological advancements in CRC screening procedures and modalities, such as fecal immunochemical test (FIT), air contrast
barium enema, and colonoscopy, have led to a decrease in
mortality from CRC since the mid-1980s [1]. Despite these
* Shyam S. Mohapatra
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Extended author information available on the last page of the article

screening tools, only 40% of CRCs are diagnosed at an early
stage (I or II) [2]. This is due in part to a lack of patient compliance, limited access to screening colonoscopy, and the
low sensitivity/specificity of more commonly used tests such
as FIT [2]. Furthermore, a “one drug fits all” cancer treatment approach has been unsuccessful in effectively reducing
cancer deaths. For these reasons, there is an urgent need to
identify new strategies for the prevention of CRC as well
as the development of effective therapeutics for advanced
disease.
Specifically, the US Veteran population represents 3% of
all cancer patients in the USA and CRC accounts for ~9%
of all cancers among Veterans [4]. This is because a large
proportion of Veterans receiving care under Veterans Health
Administration (VHA) have poor health, multiple comorbidities, and lower income [3]. Further, the incidence of cancer
among Veterans is likely to increase with the aging population, an increase in military personnel, and an increase
in Veterans seeking health care in VHA [4]. VHA has
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supported a Precision Oncology Program (POP) that uses
multi-gene, next-generation sequencing (NGS) panels for
patients diagnosed with Stage III or IV CRC, with an intent
to provide precision cancer treatment (PCTx). These panels
screen for ~ 200 genes, cost about $1500 per panel, have a
turnaround time of about 2 weeks, and are not validated
for PCTx use. Also, since genomic testing only provides a
predictive approach, several tumor spheroid culture systems
have been examined for their potential use in PCTx, but this
technology also has several critical barriers. Thus, there is
a need to integrate genomics and cell-based approaches,
referred to as “cell-genomics,” to accurately diagnose, prognosticate, and treat gastrointestinal malignancies including
pancreatic and CRCs. To this end, in a VA R&D supported
field-based meeting, a panel of CRC experts met to review
research advances on the biology, biomarkers, and treatment
of CRC. The panel discussed the state-of-the-art science,
challenges, and opportunities and pragmatically established
a “VA Colorectal Cancer Cell-genomics Consortium”
(VA4C) with the goal of fostering multi-site collaborative
studies aimed at early detection, prevention, and diagnosis as
well as novel treatments for CRC. This review summarizes
these discussions on the latest developments in biology and
biomarkers to individualize diagnostics and prognostication
and precision oncology approaches, and charts future collaborative research directions.

Precision Diagnostics and Prognostics
for CRC
Advances in Biology, Biomarkers, and Imaging
for Early Detection of CRCs
To date the principal modalities for identifying early-stage
CRCs have been through use of screening colonoscopy or
fecal-based methods such as FIT. The rationale for this
approach is to identify either polyps (precancerous) or
early-stage CRCs before they develop into lethal tumors.
Early-stage CRC is curable with surgical treatment, whereas
advanced or metastatic disease may only be treated to prolong survival without curative intent [5]. The traditional paradigm is that sporadic CRC progresses in a stepwise fashion
from normal epithelium, to aberrant crypt foci, to low-grade
then high-grade adenomas and ultimately to adenocarcinoma
which may then metastasize to other organs. This pattern
of tumor progression was first identified by Vogelstein and
colleagues some 30 years ago [6]. It is now known that cancer cell heterogeneity and other factors can modulate this
progression. For example, recent studies suggest that CRCs
originating from different locations may have different metastatic targets, for example, colon cancer spreads primarily
to liver, whereas rectal cancer spreads primarily to lung
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[7]. Moreover, early in tumorigenesis, some cells within
the primary tumor already possess the ability to invade and
seed distant organs [8]. Such cells have acquired mesenchymal traits through the epithelial-to-mesenchymal transition (EMT). EMT is defined by a variety of genetic and
morphological changes, which allow cells to invade normal
colon epithelium, vascular endothelium, and eventually the
parenchyma of target organs. Recent work indicates that the
genetic signatures identifying EMT may also be cell contextdependent [9]. Metastatic cell deposits may grow slowly or
lie dormant until circulating and stroma-dependent factors
stimulate their arousal and growth.
An important anatomical factor very specific to CRC is
the recently identified “serrated polyp-neoplasia” pathway
[10–12]. Sessile serrated adenoma/polyps (SSA/Ps), established precursors of CRC, exhibit microsatellite instability
(MSI) and account for approximately 15–30% of sporadic
CRCs [13]. SSA/Ps are predominantly located in the right/
proximal colon and observed in “interval cancers” occurring
within a short time after a screening procedure (2–6% of
all CRCs) [14, 15]. Serrated polyps are characterized by a
variety of histologic features including irregular distribution
of crypts, dilatation of crypt bases, serration at crypt bases,
branched crypts, horizontal extension of crypt bases, dysmaturation of crypts, and herniation of crypts through the muscularis mucosae [16]. According to the American Gastroenterology Association criteria, even one crypt showing any
of the above characteristics is sufficient to diagnosis SSA/P.
Approximately 17.6% of SSA/Ps (> 2 cm) show residual
adenomatous tissues when reexamined [17]. Unlike other
adenomatous polyps, SSA/Ps are characterized by mutations
in the BRAF proto-oncogene that causes the development of
polyps. Hyper-methylation of CpG islands in the promoter
regions of tumor suppressor genes, including MLH1, leads
to a decrease in tumor suppression and an increase in sporadic MSI [10, 18–21]. Because benign hyperplastic polyps
(HPs) and SSA/Ps have a different risk of developing into
malignant disease, their accurate classification is critical
for making clinical decisions (e.g., surveillance intervals,
intervention). Understanding these complex processes and
testing all prognostic and therapeutic measures in animal
models before proceeding to clinical trials is challenging.
It is noteworthy that although colonoscopic screening and
polypectomy have led to a decline in advanced CRC, its
utility for differentiating SSA/Ps from HPs has not yet been
realized.

Genetic and Epigenetic CRC Biomarkers
The multistep process of CRC development is associated
with the accumulation of genetic and epigenetic alterations in epithelial cells via distinct molecular pathways,
including the common “adenoma-carcinoma” pathway as
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well as the recently identified “serrated polyp-neoplasia”
pathway [6–8]. Hence, identifying these CRC molecular
markers, i.e., biomarkers, is key to early detection, staging,
and assessment of therapeutic efficacy, as reviewed recently
[22]. Whereas current guidelines recommend surgery alone
for Stage I and adjuvant chemotherapy for Stage III cancers, the appropriate treatment for Stage II cancers, which
have breached the colon wall but not invaded lymph nodes
or other organs, is uncertain. Although it is proposed that
molecular biomarker panels, including genetic, epigenetic,
protein and carbohydrate-based markers, may identify Stage
II cancers that warrant aggressive treatment after surgical
resection [23], none have been validated prospectively.
Circulating tumor DNA and RNA-based biomarkers
offer high specificity and are ideal as predictive biomarkers for monitoring the response to chemotherapy as well
as tumor progression, as reviewed recently [24]. However,
due to low DNA yields and low mutational burden, they are
inadequate for diagnosis. Cell-free microRNAs (miRNAs)
and small non-coding RNAs (ncRNAs) are now emerging as
noninvasive and highly sensitive biomarkers, but specificity
remains a concern. For these reasons, large-scale prospective
clinical studies aimed at carefully evaluating the sensitivity
and specificity of these biomarkers are needed before their
adoption to clinical practice.
Hereditary cancer syndromes have provided powerful
insights into our understanding of somatic mutations present in sporadic cancers, as well as implicated cell signaling pathways [20–24]. One clear example is the identification of germline, inactivating mutations in the APC gene,
which encodes a 300-kD wnt pathway adaptor protein [23].
Although germline mutations in APC are responsible for
familial adenomatous polyposis (FAP), a rare condition
affecting about 1 in 7000 individuals in the USA, somatic
mutations in the APC gene are present in more than 70% of
colonic adenomatous polyps and carcinomas [24]. Hereditary non-polyposis colon cancer (HNPCC), or Lynch syndrome, involves a germline mutation in a DNA mismatch
repair (MMR) genes, leading to defective DNA repair.
Recent studies identifying inactivation of TGF-β signaling through loss of the Smad3 adaptor ß-2 spectrin could
potentially provide new insights into CRC development
from stem-like tumor-initiating cells (STICs) for targeted
chemoprevention.
Further, genome-wide association studies (GWAS) have
identified numerous genetic loci that are associated with
CRC, but hereditability remains unknown. More than 40
low-penetrant polymorphic variants are reported [25]. More
recently in a Finnish cohort, a single-nucleotide polymorphism (SNP) rs992157 at chromosome 2q35 intronic to
PNKD and TMBIMI was found to be associated with CRC
[26]. Genome-wide alterations in DNA methylation influence gene expression resulting in altered aberrant crypt foci,
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an early precursor of CRC [27]. Recently, single-cell RNA
sequencing (e.g., GemCode technology 10 × Genomics, San
Francisco, CA) has permitted an assessment of transcriptional events that may be important in the development of
cancers and could potentially predict therapeutics. In addition to genomic profiling approaches, depending upon the
molecule of interest, several additional “omics” approaches
are being utilized, including proteomics, metabolomics, lipidomics (chloroform/methanol), glycomics (glycoprotein isolation), and peptidomics.

TGF‑β Receptor and SMAD Gene Mutations
in Gastrointestinal/CRC
In normal and premalignant cells, TGF-β enforces homeostasis and suppresses tumor progression through tumor-suppressive effects on the stroma. Current data strongly support
TGF-β signaling as a suppressor of early CRCs [28, 29]. In
advanced disease, metastatic CRCs escape the tumor suppressor effects of TGF-β signaling by becoming resistant to
TGF-β-induced growth inhibition [30]. Inactivating mutations in the TGFBR2 gene occur in most human CRC and
gastric carcinomas that demonstrate MSI [31]. The TGF-β
signaling network is also disrupted in cancer by mutations
in Smad4, which occur in more than 30% of CRCs [32, 33].
Smad-deficient mice display phenotypes that suggest a tumor
suppressor role for the Smads [34]. When mice with one
mutated APC allele are crossed with heterozygous Smad4
mice, the compound heterozygotes develop larger polyps that
can progress into malignant adenocarcinomas [35]. Although
fewer Smad3 mutations have been found in human cancers,
mice with a Smad3 homozygous deletion develop aggressive CRC at an early age in a manner that seems to be highly
dependent on the genetic background of the mice.
Cross talk between CEA, TGF‑β signaling, and STAT3
Figure 1 depicts cross talk between carcinoembryonic antigen (CEA), TGF-β signaling, and STAT3. Advanced CRC is
associated with high levels of circulating CEA and a dismal
survival; the elevated levels of CEA are especially associated with Stage IV cancers. Consequently, there is a need
to identify new targets for both the prevention of CRC as
well as the development of novel therapies for advanced
cancer. CEA (also known as CEACAM5) is one of the few
biomarkers approved by the U.S. Food and Drug Administration (FDA) for CRC [36]. TCGA studies have validated
that elevated CEA levels and disruption of TGF-β signaling
are observed in over 80% of right-sided CRCs [37]. Activation of STAT3 is also observed in this subgroup of patients.
TGF-β induces the secretion of CEA in a dose-dependent
manner [38]. Given the importance of CEA, TGF-β, and
STAT3 signaling pathways in CRC tumorigenesis, cross talk
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Fig. 1  Schematics of cross talk
between CEA, TGF-β signaling,
and IL6-STAT3 pathway

between these pathways is a focus of investigation. CEA and
CEACAM6 are known Smad3 target genes. An important
direction for the future is designing studies that delineate the
molecular mechanisms underlying the cross talk between
CEA and the TGF-β and STAT3 signaling pathways during
CRC development.

Mucins as Biomarkers for CRC Early Detection
and Prognosis
Several studies showed moderate to high inter-observer
disagreement between pathologists in the histologic differentiation of SSA/Ps (highly malignant) and HPs (benign)
[21, 39–46]. Considering this variability, studies have
focused on identifying molecular markers for distinguishing
between these two entities. For example, MUC5AC, TFF1,
and Annexin A10 have emerged as potential markers for
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differentiating benign polyps from SSA/P [47, 48]. Aberrant
changes in the expression, localization, and glycosylation
of colonic mucin have been observed in very early stages of
colon cancer. SSA/Ps exhibit an elevated expression of transmembrane mucin MUC17 and secreted mucin MUC5AC in
comparison to HP [49]. Notably, in conjunction with these
expressional changes, distinct differences were also observed
among the studied polyp groups in MUC5AC and MUC4
localization. This signifies the ability of these markers to
discriminate benign HP from SSA/P polyp subtypes. In multivariate regression models in conjunction with ROC curve
analyses, the combination of MUC17/MUC5AC effectively
discriminated SSA/Ps from HP [49]. The trio (CA 19-9,
MUC17, and MUC5AC) emerged as a combined panel for
discriminating polyp subtypes and thus accurately classifying colorectal polyps. Based on the lack of clear tools to
identify SSA/Ps, histologic markers can aid in improving
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the differentiation of SSA/Ps from benign polyp subtypes.
Due to difficulties in their diagnosis by endoscopists, their
inter-observer variability among pathologists, and their
highly malignant nature, a means of identifying SSA/Ps is
central to the improved detection and timely treatment of
CRC. There is a broad consensus that future studies should
focus on identifying alternative molecular markers that can
more successfully achieve these goals.

Biomarkers for Colon Cancer Dissemination
One novel approach to stratify the malignant potential of
CRC is to identify cancer cells with distinct invasive potential at the tumor “front,” namely the interface between tumor
and normal tissue. Nuclear accumulation of β-catenin distinguishes the cells at the “front” from those closer to the
tumor core [50]. This is consistent with observations that
cells tend to invade in clusters, not as individuals [9]; these
cells likely share attributes that predispose them to behave as
an aggressive unit. Cell clusters at the tumor front are more
likely to co-overexpress M3 muscarinic receptors (M3R)
and matrix metalloproteinase-1 (MMP1) within cytoplasmic vesicles [51]. This is potentially important since M3R
activation robustly induces expression of MMP1, a secreted
collagenase that promotes colon cancer invasion [52–54].
Validating the use of such histochemical tests in formalinfixed paraffin-embedded tissues may yield an efficient and
economical way to identify those Stage II cancers that
require more aggressive therapy.

Histopathology with Neuroendocrine Tumor (NET)
Stains Identifies Neuroendocrine Features of CRC
A subset of adenocarcinomas and adenomas possess neuroendocrine features [55]. Neuroendocrine cells possess bioactive
amines and peptides that may have an important role in promoting the growth of transformed cells such as those within
adenocarcinomas, as has been demonstrated with peptides
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such as PACAP [56]. The expression of receptors on CRCs
can differentially couple to intracellular signaling molecules
that promote proliferation [57]. A recent study identified neuroendocrine features in up to one-third of 40 patients with
CRC (unpublished data); assays of chromogranin A and neuron-specific enolase were performed (Fig. 2). The presence of
neuroendocrine features may suggest a stem cell component
or portend a more aggressive tumor state. Neuroendocrine
features may also suggest different chemotherapeutic or biologic strategies in advanced-stage CRC.

Role of Microbiome in CRCs
Well-established risk factors for colorectal adenomas and
cancer include: a personal or family history of CRC or polyps; an inherited condition that predisposes to colon polyps
and cancer; inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis); obesity; type 2 diabetes; heavy
alcohol use; a diet high in red meat and processed meats;
smoking; and physical inactivity. Additional risk factors that
have been described include fatty liver [58], hepatitis C [59],
and Agent Orange exposure [60]; the latter is very relevant
to Vietnam Veterans. Modifying known dietary and lifestyle
risk factors and chemoprevention with aspirin and nonsteroidal anti-inflammatory drug (NSAID) use are associated with
reduced risk for colon polyps and CRC [61]. In relation to
the role of the diet and intestinal microbiome in CRC pathogenesis, the microbiome of subjects consuming a Western
diet (WD) was compared to that of subjects consuming a
high-protein diet (HPD) [62] (Fig. 3a, b). There was a highly
significant difference in composition by weighted UniFrac
analysis (p < 10−5) (Fig. 3b). At the genus level, the HPD
microbiome was characterized by expansion of Akkermansia,
Ruminococcus, and Bacteroides and depletion of Lactobacillus and Turicibacter (Fig. 3c). The HPD group had increased
abundance of 114 operational taxonomic units (OTUs)
selected at 97% similarity (corresponding approximately to

Fig. 2  a NET features by H&E staining in colorectal adenocarcinoma specimen. b NET features by chromogranin A immunohistochemistry
staining in colorectal adenocarcinoma specimen. Unpublished data
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species) at a threshold of q < 0.05 (representing significance
adjusted for multiple hypothesis testing).
Of these, only Akkermansia mucinophila (q = 0.008) and
an unclassified Clostridiales (q = 0.04) had a statistically
significant inverse correlation with fat mass after adjustment for diet [62]. Fusobacterium enrichment is associated
with specific molecular subsets of CRCs, suggesting that
there is a potential pathogenic role in the development of
CRC [63]. Furthermore, it has also been shown that environmental pollutants may affect the microbiome, such as was
observed with ultrafine particles [64]. Whether ultrafine particles affect the steps involved in colon cancer pathogenesis
remains to be investigated.

Precision Imaging for Prevention of CRCs

Digestive Diseases and Sciences (2018) 63:1123–1138

a primary performance benchmark [72]. To this end, standard
colonoscopy has undergone recent enhancements to improve
detection of more subtle lesions and has been supplemented
with other technologies that provide “real-time histology” to
enable selective removal [73–75]. Clinical trials, however,
have shown that both high definition colonoscopy and dye
spray chromoendoscopy only marginally improve neoplastic polyp detection [76, 77]. Using retrograde and ultra-wide
angle camera systems that reveal surface area between folds
can improve neoplastic polyp detection by 23–70% [78, 79].
Selective wavelength imaging and transparent cap-assisted
colonoscopy have had mixed results [80, 81]. Thus, despite
some improvements there remains a major unmet need in the
ability to detect and remove atypical and serrated polyps.

Screening colonoscopy has emerged as perhaps the most
effective lifesaving intervention against CRC to date. Pooled
analysis of numerous large observational studies indicates that
systematic removal of all visualized polyps including adenomatous and serrated polyps [43, 65] at colonoscopy decreases
proximal and distal CRC incidence and mortality by > 60%
[2]. Currently, a VA clinical trial (50,000-subject, prospective randomized controlled study) is underway (Cooperative
Studies Program #577) to assess screening colonoscopy versus FIT for reducing CRC deaths. While cancer death rates
in persons older than 50 years are now declining, likely due
to the adoption of screening programs, recent data indicate
that age-specific CRC incidence and mortality are actually
rising in those < 50 years of age. Colonoscopy has not been
fully protective due to several uncontrollable factors including
missed polyps, operator factors [66–69], and an inability to
detect atypical [70] serrated polyps and poorly visualized flat
neoplasms [71]. Thus, colonoscopy can benefit from assistive
technologies that improve the neoplastic polyp detection rate as

CRC: Advances in Precision Surgery
and Treatment

Fig. 3  A high-protein diet induces fat loss and an altered intestinal
microbiome in rats with Western diet-induced obesity. a Body fat
mass of rats kept on a WD or switched to a HPD. Age-matched control rats on a ND are shown for comparison. **p < 0.01 b Principal

coordinates analysis (PCoA) of the cecal luminal microbiome colored
by diet. P value across groups calculated using Adonis. c Mean abundance of common genera. Some reads were identified only at the family (f) or order (o) level
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Although surgical resection is the mainstay of treatment in
early-stage CRC, incomplete removal of tumors leads to
local or widely metastatic disease which is resistant to conventional chemotherapeutics. For patients whose disease has
progressed to metastatic CRC, molecular profiling may shed
light on why various treatments fail. The discussions in this
section focus first on advancing CRC precision treatment
through increased precision in CRC surgery. Secondarily it
reviews the state of the art in targeted chemotherapies.

Fluorescence‑Guided Surgery for CRC
Surgical resection for CRC has the greatest potential for
cure. Since the application of complete mesocolic excision for colon cancer surgery, local 5-year recurrence rates
have decreased [82]. Furthermore, achieving negative
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microscopic margins and complete resection of metastatic
tumor (R0 resection) can significantly improve 5-year survival rates [83–87]. Despite achieving R0 resection rates
in patients with CRC, local and distant recurrence has still
been reported to be as high as 34% [84, 88, 89]. Furthermore, the prognosis of patients with local recurrence is poor
[90]. Real-time, reliable imaging to detect positive surgical
margins at the time of surgery would improve outcomes.
Emerging techniques are revolutionizing the performance
of cancer surgery [91]. Intraoperative fluorescence imaging, or fluorescence-guided surgery (FGS), can provide high
fidelity tumor visualization for localization, resection, and
margin confirmation [92]. Thus, targeted fluorescent labeling of cancer cells may change the way we find and treat
cancer [93, 94].
FGS combines advanced imaging platforms with targeted
fluorescent agents to improve their intraoperative detection
[95]. One technique is to covalently bind organic dye to a
monoclonal antibody which labels a known tumor-specific
antigen [91]. One such tumor biomarker is anti-CEA antibodies which label human CRC in murine models [92,
96–98] (Fig. 4). Mouse and chimeric (mouse/human) CEA
antibodies, conjugated to fluorescent dyes, are capable of
enhancing visualization of submillimeter tumor deposits
[92] and aiding with FGS [99–101]. In an effort to improve
therapeutic efficacy in the clinic, Yazaki et al. [102] humanized the murine anti-CEA T84.66 antibody with structurally
similar “human” segments through a technique known as
complementary determining region (CDR) grafting. This
humanized anti-CEA antibody is currently used in clinical trials for PET imaging of CRC. In Europe, this technique was recently applied in clinical trials to localize CRC
using SGM-101, an antibody-dye conjugate in which the
fluorochrome BM104 is coupled to a chimeric monoclonal
antibody against CEA [103]. Other fluorophore-conjugated
antibodies to tumor-specific antigens such as insulin-like
growth factor-1 receptor have been used in preclinical FGS

Fig. 4  Labeling of orthotopic human colon tumors in nude mice with
fluorophore-conjugated chimeric anti-CEA antibodies. Panel A shows
bright-field image of an orthotopic colon tumor (white arrow) and
panel B shows the bright fluorescence of the tumor 48 h after labe-
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for colon cancer [104]. In addition, viral vectors such as adenovirus and herpes virus can be used to deliver fluorescent
proteins to cancer cells [105]. Activatable cell-penetrating
peptides have been engineered to highlight tumors based
on enzymatic cleavage of peptidases [106]. Indocyanine
green (ICG), used clinically to define liver tumor margins,
tissue perfusion, and biliary anatomy, has been shown to
reduce leak rates after low anterior resection for CRC [107].
Thus, the use of FGS as a surgical guide has the potential to
increase both survival and quality of life for patients [108].
FGS has great potential for a broad range of clinical applications, including in CRC.

Targeted Chemotherapies
Targeted therapies have recently been developed to join traditional therapeutic approaches to CRC including surgery,
chemotherapy, and radiotherapy [109]. Targeted chemotherapy may be used for neoadjuvant treatment or adjuvant
treatment. For advanced cancers that have spread to other
organs, such as the liver, chemo can also be used to help
shrink tumors and relieve symptoms. Although it is not
likely to cure the cancer, it often prolongs life. Common
drugs used for CRC include: 5-fluorouracil (5-FU), often
given with leucovorin (also called folinic acid) or levo-leucovorin; capecitabine (Xeloda tablets) metabolized to 5-FU
in tumors [110]; irinotecan (Camptosar); and a combination
tablet containing oxaliplatin (Eloxatin) and trifluridine and
tipiracil (Lonsurf).
About 85% of all sporadic CRCs occur due to chromosomal instability, and ~ 15% of all CRCs are caused by various deficiencies in the DNA mismatch repair system. In the
order of decreasing frequencies, TP53, KRAS, PIK3CA,
BRAF, and PTEN are among the most commonly altered
genes in CRC [111]. TP53 was the most commonly mutated
gene, affecting 17/24 cell lines; hyperactivating KRAS mutations were found in 15 cancer cell lines of which five were

ling the fluorophore chimeric anti-CEA antibodies. The absence of
any fluorescence signal after fluorescence-guided surgery in panel C
indicates a complete resection
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homozygous, and BRAF mutations were found in another
five cell lines.
Several cutting-edge biological modalities are under
investigation. Mannosylated liposomes have been used to
improve cell uptake and tumor inhibition rate [112]. This was
shown without increase in toxicity. Thus, Patras et al. [113]
have shown the effects of liposomal paclitaxel encapsulated in long-circulating liposomes together with liposomal
prednisolone phosphate to be superior in anti-tumor activity mainly related to anti-angiogenic and anti-inflammatory
effects. Attempts have been made to detail the functional
pathways microRNA array, and considerable knowledge
has been accumulated [114]. Yao et al. [115] have shown
the importance of microRNA-215 as a tumor suppressor in
colon cancer, which paradoxically acts as oncogene in breast
cancer, and have proposed this to be a novel therapeutic
target. However, knowledge of several microRNAs is very
limited in terms of their targeted genes [113, 114]. Zheng
et al. studied the effects of caudal type homeobox (CDX2)
and human telomerase reverse transcriptase (hTERT) [115].
hTERT and loss of CDX2 have been associated with colon
cancer in humans. In their elegant experiment, they showed
over-expression of CDX2 is associated with suppression of
colon cancer progression [116]. Finally, as stated before,
TGF-β has also been implicated in treatment of metastatic
colon cancer [117].

Immunotherapies for CRC
Immune surveillance is a key mechanism to protect against
malignancy. Successful CRC immune surveillance relies
on the effective function of antigen-presenting cells and T
cells. It is now evident that this inadequate function of host
immune system is due to suppressive factors like myeloidderived suppressor cells (MDSCs). It is one of the major
mechanisms of tumor escape from immune control as
well as an important factor limiting the success of cancer
immunotherapy. MDSCs play an important role in tumor
non-responsiveness by suppressing antigen-specific T cell
responses [118–121]. These cells take up antigen delivered
by vaccination, present it to activated T cells, and thereby
inhibit the same antigen-specific T cells that the vaccination strategy is aiming to activate. Cancer patients or tumorbearing mice have a considerable number of MDSCs, which
cause even the most effective antigen-delivery strategies
to fail [120, 121]. CRC therapy will only be successful if
strategies involve either the differentiation or elimination of
suppressive cells. This strategy will be more effective than
direct cancer therapy that attempts to eliminate tumor cells.
Consideration of immune suppressive parameters will provide better stratification of CRC patient treatment.
Currently there are about 46 active (recruiting) immunotherapy trials against CRC (Clin Trials. Gov accessed

13

Digestive Diseases and Sciences (2018) 63:1123–1138

on July 23, 2017). Peptide vaccines targeting HER-2/Neu,
P-53, SART-3, and CEA in CRC have been studied. These
vaccines are generally well tolerated but are far from a successful treatment. Most of the current CRC immunotherapies can be grouped as checkpoint blockade inhibitors like
anti-CTLA4 [122], PDL-L1 [123], PD-1 [124], LAG-3;
approved FDA targeted antibodies like bevacizumab, cetuximab, ramucirumab, and panitumumab; ACT (adoptive T cell
therapy) and virus-mediated therapies. These therapies are
tried either as adjuvants or as combinations. Current CRC
immunotherapy targets the highly expressed tumor antigens
like CEA, APC, MAGE, MUC-1, and survivin [125], or
common mutations in the WNT, MAPK, TGF, P53, or apoptosis pathway [126–128]. A recent paper targeting mutant
KRAS in CRC patients using ACT observed objective progressive regression [129]. ACT targeting various known
CRC mutations in combination with checkpoint inhibitors
and modulating the persistent immune suppressive factors
would lead to effective therapies. Data from a phase 2 trial of
pembrolizumab for the treatment of tumors with and without
mismatch repair deficiency support the hypothesis that mismatch repair-deficient tumors are more responsive to PD-1
blockade than are mismatch repair-proficient tumors [130].

Emerging Approaches to Personalizing
Cancer Treatment
Genomic Testing
Personalizing cancer treatment that is tailored to an individual’s genomic profile is a cornerstone of precision
oncology [131]. NGS of DNA from tumor tissue can identify gene variants that could be targets of specific cancer
therapies. These variants can be inherited (germline) or
acquired (somatic) [132]. For example, poly(ADP-ribose)
polymerase (PARP) inhibitors are effective in killing cancer
cells that are deficient in repair of double-stranded DNA
breaks. This is due to a pathogenic variant in the BRCA1 or
BRCA2 gene [133] and other germline variants, which cause
hereditary breast-ovarian cancer syndrome [134]. Tumors
deficient in DNA mismatch repair (MMR) due to a pathogenic variant in the MSH2, MLH1, MSH6, PMS2, or EPCAM
genes are responsive to antibodies or ligands that block the
programmed death 1 (PD1) pathway [130]. These germline
variants cause Lynch syndrome, the most common cause of
hereditary CRC [135].
The VHA has undertaken feasibility studies on the use
of NGS testing of tumor samples [136]. Tumors tested with
multi-gene NGS sequencing through 1 of 2 contracted vendors were identified from POP records, and cancer characteristics were extracted from POP and medical records.
Drug use data were obtained from the VA Corporate Data
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Warehouse. NGS testing results and annotations were
extracted from POP records. Of a total of 1292 tumor samples sent for NGS testing since program inception in 2015,
the most common diagnoses have been lung (561: adeno
418, squamous 143), gastrointestinal [109], lymph node
[75], liver [56], head and neck [52], and prostate [43]. The
rate of sample test requests increased rapidly after national
dissemination in July 2016 (from a mean of 23 samples/
month prior to launch to a mean of 126 samples/month
3 months later), as did the number of participating facilities
(from a mean of 8/month to a mean of 27/month). Sequencing success rate increased from 68 to 71% over the same
interval, while mean turnaround time remained similar at
19.7 and 19.1 days, respectively. NGS was requested for 61
patients with CRC, with almost all requested after dissemination of POP across the USA. Only one case failed to generate NGS results (98% success rate). Twenty-two patients
had mutations targetable with an off-label FDA-approved
drug, but no patient received NGS-directed treatment. These
results suggest that tumor NGS testing as part of POP in the
VA healthcare system is feasible with a high rate of testing success in CRC, but effective implementation strategies
are needed to ensure uptake of treatments targeting tumor
sequencing results.

The Spheroid and Organoid Culture Approaches
to Assess Clinical Drug Response
Animal models of human CRC do not recapitulate human
disease and frequently yield overly optimistic results [137,
138]. In the absence of accurate murine models, robust cellular models of CRC are considered critical. With over 150
CRC cell lines having been investigated, there is an abundance of cell line resources to investigate [139]. A number
of different colon two-dimensional (2D) cell techniques,
also referred to as “flat” cell cultures, have been described
including the flow cell used for organ-on-chip models [140].
Despite progress made, these flat cultures are significantly
different from in vivo tumor cells biochemically, physiologically, and genetically. Another approach that has been developed is in vitro multi-cell tumor-like cultures referred to
as spheroids, tumoroids, or organoid culture systems [141].
Whether they are scaffold-free or scaffold-based 3D platforms, they fail to fully recapitulate in vivo tumors [141].
More importantly, they are cumbersome, costly, and not
adaptable to perfusion-driven culture. Though very few of
these have progressed to clinical testing realm the spheroid
technologies are under intense investigation for their use in
clinical drug response analyses.
Notably, several studies reported success in predicting
CRC clinical drug response using organoid culture, also
referred to as histoculture technique. Thus, an evaluation of
86 chemotherapy regimens using the 3D histoculture drug
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response assay (HDRA) for CRCs showed that the correlation of HDRA to the clinical response to chemotherapy
was 66% (sensitivity 73%, specificity 55%) [142]. In another
study, ATP-CRA-guided chemotherapy group showed better treatment response (48.4 vs. 21.9%, p = 0.027) and a
higher rate of resection of hepatic lesions (35.5 vs. 12.5%,
p = 0 [143]. Also, the extreme drug response assay (EDRA),
developed as an exclusion test to identify drugs unlikely to
elicit a response [144], was used to analyze the therapeutic
efficacy of treatment for CRC patients. Thus, in the clinical
correlation of 25 Duke’s D patients with EDRA, the sensitivity and specificity of the assay were 100 and 95%, respectively, suggesting that EDRA obtained at initial diagnosis
may be useful for the selection of therapeutic regimens for
metastatic disease [145, 146]. While these studies indicate
the value of ex vivo organoid cultures, these results need to
be replicated in multicenter clinical trials.

Tumoroid Technology for Clinical Drug Response
A fiber-inspired smart scaffold (FiSS) tumoroid culture platform has been developed that allows the formation of tumorlike organoids with molecular signatures of tumors. These
cancer cells obtained from ex vivo tumor biopsies mimic
patient tumors [141, 147, 148] (Fig. 5). The novelty of this
platform lies in its simplicity, reproducibility, and similarity
to in vivo tumors in terms of its drug responsiveness. Recent
pilot proof-of-concept studies showed that cells of tumors
from cancer patients, when cultured on a tumoroid platform,
formed tumoroids that exhibited differential drug response
[141, 147, 148]. Tumoroids were also found to expand cancer stem cells (CSCs) up to 30-fold, with cancer cells originating from several cancer cell lines including cells from
breast, lung, and colon tumor xenografts.
In the post-genomic era the development of microarray
technology has allowed use of genomic data to help define
which patients would benefit most from a specific therapy
[149]. For example, gene signatures have been developed
and validated against large retrospective databases to risk
stratify patients to selectively receive adjuvant treatments
for breast cancer [150]. However, genomic/genetic tests
are based on pathway analysis of several genes with mutations out of more than 1000 genes that play a role in cancer
pathogenesis. They may reveal potential adverse responses
to drugs. However, the results do not indicate one or two
potential drugs for effective treatments but rather suggest
excluding therapies that may cause adverse effects.
One novel approach to PCT involves use of the patientderived perfused tumoroid (PPT) platform, which mimics
patient’s tumor. PPT provides a simple, rapid, scalable, and
inexpensive in vitro tumor model that better replicates the
structure, physiology, and function of tissues. It also recreates the in vivo morphology and arrangement of individual
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Fig. 5  Schematics of tumoroid technology platform for anti-CSC drug discovery and tumoroid-based clinical drug response assay

cells and the concentration gradients of both signaling
molecules and therapeutic agents [151]. This platform can
be used to culture tumoroids utilizing human tumor cells
(Fig. 5) with or without stromal cells. These are derived
from biopsy or surgery discard tumor samples from patients.
The PPT also promotes tumoroids in a manner that can be
adapted for cell viability measurements (e.g., Celltiter-Glo
or PrestoBlue). Preliminary data suggest that PCT tests
will fully recapitulate in vivo tumors and will provide evidence for the best drug to treat each patient’s tumor. Further,
expanding PCT to include first genetic/genomic testing that
predicts potential therapies, followed by tumoroid-based
clinical drug response assay, is expected to significantly
improve the standard of personalized therapy. Adding
evidence-based, simple-to-analyze, and ready-to-prescribe
therapies will significantly improve personalized cancer
treatment. Thus, a cell-genomic approach that combines
NGS-based genomic testing with a PPT-based clinical drug
response assay is expected to provide an exciting approach
for PCT and may aid in discovery of novel anticancer agents.

Cancer Stem Cell Biology and Drug Discovery
Pivotal to successful CRC treatments are CSCs, referred to
as the “seeds” of tumors, which play a central role in processes such as tumor initiation, drug resistance, invasion,
and metastasis. While chemo-, radio- and immune-therapies are more effective at killing bulk tumor cells, the quiescent CSCs manage to escape and seed new tumor growth.
CSC phenotype in human colon cancer is associated with
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poor prognosis [152, 153]. Hence, a therapeutic approach
has been to target CSCs through either inhibition of selfrenewal or induction of differentiation [154, 155]. A major
barrier to CSC research, however, is the small proportion
of these cells in tumors. With the possibility to expand
CSCs by tumoroid cultures has opened new avenues for
anti-CSC drug discovery. An NCI library of FDA-approved
drugs was screened using FiSS tumoroid platform, which
revealed that mithramycin A, idarubicin, and daunorubicin
were the most potent inhibitors of HT-29 cell viability; and
cisplatin, 6-thioguanine, and cytarabine were the least potent
inhibitors. Further studies have revealed that mithramycin A
treatment can reduce CSC self-renewal as well as expression
of stemness genes. These results suggest that mithramycin A
may be used as a single agent or in combination with other
chemo- or immuno-therapy to most effectively treat or possibly ‘cure’ CRCs.
In addition to these efforts, two major pathways have been
exploited to screen for anti-CSC drugs. First, application of
HTS on a library of small molecules targeting EMT in breast
cancer cells led to identification of four candidates: salinomycin, a polyketide synthase-derived natural product, and
probes ML239, ML243, and ML245, which are chemically
synthesizable, small hydrophobic molecules [156–160]. A
second target signaling pathway for CSCs involves interaction of glycosaminoglycans (GAGs) with factors involved in
growth and/or differentiation signaling that regulate CSCs,
including growth factors (e.g., fibroblast growth factors,
TGF-β, bone morphogenetic proteins), cytokines (e.g., interleukins-6 and -8), or morphogens (e.g., Hedgehog, Notch).
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These in turn influence many transcription factors including
Nanog, Oct4, and SOX2 and c-MYC, which play critical
roles in deciding the fate of CSCs [161–163]. In sum, the
identification of only four CSC targeting molecules so far
using CSC-pathway screening approach for breast CSCs
highlights the difficulty of targeting CSCs. For the anti-CSC
paradigm to translate into therapeutic success, a more fundamental and generalizable approach is needed.

Concluding Remarks and Opportunities
Our review has identified key research directions in the
field of CRC, as summarized below. a) Current genomic
testing includes primarily somatic mutations only, and not
genetic testing for germline mutations. Adding the latter
might allow for more accurate CRC risk assessment, surveillance and prevention. Also, marker(s) such as specific
mucins could serve as a powerful adjunct to colonoscopy by
enabling efficient detection of SSA/Ps. b) Several emerging
genetic biomarkers as well as cell-free miRNAs and small
non-coding RNAs have been suggested as noninvasive and
highly sensitive candidate markers for CRCs. They will
require large clinical trial-based validation. c) In relation
to precision treatment approaches, developments in ex vivo
cell-genomics technologies and the potential to combine
genomic/genetic testing with tumoroid-based drug response
testing might provide more accurate clinical efficacy of certain drugs in individual patients. d) Integrating targeted
tumor imaging preoperatively and delineating tumor margins intraoperatively with fluorescent labeling can improve
the precision of surgical resection. e) Given the pivotal role
of cancer-initiating stem cells in CRC progression, the stem
cell niches discovered thus far, such as CEACAM/TGF-β
and M3R, need further investigation. Other stem cell niches,
such as telomerase, CTCF, CEA, E-cadherin, and β-catenin,
may be equally important in developing targeted, preventive
therapies against CRC. f) CRC tumoroid/organoid technology using polymeric nanofiber scaffolds to expand CSCs
ex vivo is of considerable interest. Specifically, tumoroid
technology can be used to expand CSCs of hard-to-detect
SSA/P neoplasms, which can be characterized and investigated for CRC stem cell niches and used for evaluating
existing chemo- and immunotherapies.
Acknowledgments This VA Colorectal Cancer Cell-genomics Consortium (VA4C) meeting was supported by a Department of Veterans
Affairs Biomedical Laboratory Research and Development Service
field-based meeting award to Dr. Shyam Mohapatra and Dr. Subhra
Mohapatra. The contents of any report, written material or manuscripts
emanating from this meeting do not represent the views of the Department of Veterans Affairs or the United States Government. The VA4C
would like to acknowledge the support of Ms. Christen Bouchard in
preparation of this manuscript.

1133

Compliance with ethical standards
Conflict of interest All authors except the following have indicated no
financial conflicts of interests in relation to writing of this review. Even
though not relevant to this review, Dr. Hemant K Roy has declared that
he is a co-founder and shareholder in startup company Nanocytomics
and American BioOptics LLC. Additionally, Subhra Mohapatra (cofounder and scientific advisor), Shyam Mohapatra (co-founder and scientific advisor) and the University of South Florida have equity interest
in Transgenex Nanobiotech Inc. The terms of the conflict management
have been reviewed and approved by the University of South Florida,
Tampa, in accordance with its conflict of interest policies.
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate
if changes were made.

References
1. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.
N Engl J Med. 2012;366:687–696.
2. Pan J, Xin L, Ma YF, et al. Colonoscopy reduces colorectal cancer incidence and mortality in patients with non-malignant findings: a meta-analysis. Am J Gastroenterol. 2016;111:355–365.
3. Nelson KM, Starkebaum GA, Reiber GE. Veterans using and
uninsured veterans not using Veterans Affairs (VA) health care.
Public Health Rep. 2007;122:93–100.
4. Zullig LL, Williams CD, Fortune-Britt AG. Lung and colorectal
cancer treatment and outcomes in the Veterans Affairs health care
system. Cancer Manag Res. 2015;7:19–35.
5. Fakih MG. Metastatic colorectal cancer: current state and future
directions. J Clin Oncol. 2015;33:1809–1824.
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
7. Qiu M, Hu J, Yang D, et al. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget.
2015;6:38658–38666.
8. Enquist IB, Good Z, Jubb AM, et al. Lymph node-independent
liver metastasis in a model of metastatic colorectal cancer. Nat
Commun. 2014;5:3530.
9. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–691.
10. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology.
2015;149:1177e3–1190e3.
11. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in
colorectal cancer: emerging biomarkers. Gastroenterology.
2015;149:1204–1225.e12.
12. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic
events generate multiple pathways in colorectal cancer progression. Patholog Res Int. 2012;2012:509348.
13. Buda A, De Bona M, Dotti I, et al. Prevalence of different
subtypes of serrated polyps and risk of synchronous advanced
colorectal neoplasia in average-risk population undergoing
first-time colonoscopy. Clin Transl Gastroenterol. 2012;3:e6.
14. Crockett SD, Snover DC, Ahnen DJ, et al. Sessile serrated
adenomas: an evidence-based guide to management. Clin Gastroenterol Hepatol. 2015;13:11–26.e1.

13

1134
15. IJSPEERT JE, Rana SA, Atkinson NS, et al. Clinical
risk factors of colorectal cancer in patients with serrated
polyposis syndrome: a multicentre cohort analysis. Gut.
2017;66:278–284.
16. East JE, Atkin WS, Bateman AC, et al. British Society of Gastroenterology position statement on serrated polyps in the colon
and rectum. Gut. 2017;66:1181–1196.
17. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal
Cancer. Gastroenterology. 2012;143:844–857.
18. Freeman HJ. Heterogeneity of colorectal adenomas, the serrated
adenoma, and implications for screening and surveillance. World
J Gastroenterol. 2008;14:3461–3463.
19. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology.
2008;135:1079–1099.
20. Yang S, Farraye FA, Mack C, et al. BRAF and KRAS Mutations
in hyperplastic polyps and serrated adenomas of the colorectum:
relationship to histology and CpG island methylation status. Am
J Surg Pathol. 2004;28:1452–1459.
21. Huang CS, O’Brien MJ, Yang S, et al. Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. Am J
Gastroenterol. 2004;99:2242–2255.
22. Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in
colorectal cancer: a systematic review of recent advances and
challenges. Biomed Pharmacother. 2017;87:8–19.
23. Felton J, Raufman JP. Is the ColDx assay a valid prognostic mrker for stage II colon cancer? Transl Cancer Res.
2017;5:S1157–S1159.
24. Singh MP, Rai S, Suyal S, et al. Genetic and epigenetic markers
in colorectal cancer screening: recent advances. Expert Rev Mol
Diagn. 2017;17:665–685.
25. Barontini J, Antinucci M, Tofanelli S, et al. Association between
polymorphisms of TAS2R16 and susceptibility to colorectal cancer. BMC Gastroenterol. 2017;17:104.
26. Tanskanen T, van den Berg L, Valimaki N, et al. Genome-wide
association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci. Int J Cancer. 2018;142:540–546.
27. Hanley MP, Hahn MA, Li AX, et al. Genome-wide DNA methylation profiling reveals cancer-associated changes within early
colonic neoplasia. Oncogene. 2017;36:5035–5044.
28. Li Y, Cao H, Jiao Z, et al. Carcinoembryonic antigen interacts
with TGF-{beta} receptor and inhibits TGF-{beta} signaling in
colorectal cancers. Cancer Res. 2010;70:8159–8168.
29. Grady WM, Markowitz SD. Genetic and epigenetic alterations in
colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101–128.
30. Hoosein NM, McKnight MK, Levine AE, et al. Differential sensitivity of subclasses of human colon carcinoma cell lines to the
growth inhibitory effects of transforming growth factor-beta 1.
Exp Cell Res. 1989;181:442–453.
31. Yashiro M, Hirakawa K, Boland CR. Mutations in TGFbetaRII and BAX mediate tumor progression in the later stages of
colorectal cancer with microsatellite instability. BMC Cancer.
2010;10:303.
32. Takagi Y, Kohmura H, Futamura M, et al. Somatic alterations of
the DPC4 gene in human colorectal cancers in vivo. Gastroenterology. 1996;111:1369–1372.
33. Takagi Y, Koumura H, Futamura M, et al. Somatic alterations
of the SMAD-2 gene in human colorectal cancers. Br J Cancer.
1998;78:1152–1155.
34. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth
control, cancer, and heritable disorders. Cell. 2000;103:295–309.

13

Digestive Diseases and Sciences (2018) 63:1123–1138
35. Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis
in compound mutant mice of both Dpc4 (Smad4) and Apc genes.
Cell. 1998;92:645–656.
36. Tiernan JP, Perry SL, Verghese ET, et al. Carcinoembryonic
antigen is the preferred biomarker for in vivo colorectal cancer
targeting. Br J Cancer. 2013;108:662–667.
37. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature.
2012;487:330–337.
38. Chakrabarty S, Tobon A, Varani J, et al. Induction of carcinoembryonic antigen secretion and modulation of protein secretion/
expression and fibronectin/laminin expression in human colon
carcinoma cells by transforming growth factor-beta. Cancer Res.
1988;48:4059–4064.
39. Michalopoulos G, Tzathas C. Serrated polyps of right colon:
guilty or innocent? Ann Gastroenterol. 2013;26:212–219.
40. Sandmeier D, Seelentag W, Bouzourene H. Serrated polyps
of the colorectum: is sessile serrated adenoma distinguishable
from hyperplastic polyp in a daily practice? Virchows Arch.
2007;450:613–618.
41. Yang HM, Mitchell JM, Sepulveda JL, et al. Molecular and histologic considerations in the assessment of serrated polyps. Arch
Pathol Lab Med. 2015;139:730–741.
42. Schreiner MA, Weiss DG, Lieberman DA. Proximal and large
hyperplastic and nondysplastic serrated polyps detected by
colonoscopy are associated with neoplasia. Gastroenterology.
2010;139:1497–1502.
43. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am
J Gastroenterol. 2012;107:1315–1329. (quiz 1314, 1330).
44. O’Brien MJ. Hyperplastic and serrated polyps of the colorectum.
Gastroenterol Clin North Am. 2007;36:947–968. (viii).
45. IJspeert JE, Vermeulen L, Meijer GA, et al. Serrated neoplasiarole in colorectal carcinogenesis and clinical implications. Nat
Rev Gastroenterol Hepatol. 2015;12:401–409.
46. Hetzel JT, Huang CS, Coukos JA, et al. Variation in the detection
of serrated polyps in an average risk colorectal cancer screening
cohort. Am J Gastroenterol. 2010;105:2656–2664.
47. Khaidakov M, Lai KK, Roudachevski D, et al. Gastric proteins MUC5AC and TFF1 as potential diagnostic markers of
colonic sessile serrated adenomas/polyps. Am J Clin Pathol.
2016;146:530–537.
48. Gonzalo DH, Lai KK, Shadrach B, et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a
sessile serrated adenoma/polyp. J Pathol. 2013;230:420–429.
49. Krishn SR, Kaur S, Sheinin YM, et al. Mucins and associated
O-glycans based immunoprofile for stratification of colorectal
polyps: clinical implication for improved colon surveillance.
Oncotarget. 2017;8:7025–7038.
50. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol.
2007;19:150–158.
51. Cheng K, Shang AC, Drachenberg CB, et al. Differential expression of M3 muscarinic receptors in progressive colon neoplasia
and metastasis. Oncotarget. 2017;8:21106–21114.
52. Said AH, Hu S, Abutaleb A, et al. Interacting post-muscarinic
receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells. Biochem J. 2017;474:647–665.
53. Raufman JP, Cheng K, Saxena N, et al. Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion
of human colon cancer cells. Biochem Biophys Res Commun.
2011;415:319–324.
54. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.

Digestive Diseases and Sciences (2018) 63:1123–1138
55. Lew EA, Lewin KJ, Zarchy T, et al. Adenocarcinoma of the colon
with neuroendocrine features and secretory diarrhea. Am J Gastroenterol. 1999;94:1692–1694.
56. Le SV, Yamaguchi DJ, McArdle CA, et al. PAC1 and PACAP
expression, signaling, and effect on the growth of HCT8, human
colonic tumor cells. Regul Pept. 2002;109:115–125.
57. Germano PM, Le SV, Oh DS, et al. Differential coupling of the
PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2 + does not
activate tumor proliferation. J Mol Neurosci. 2004;22:83–92.
58. Ze EY, Kim BJ, Jun DH, et al. The fatty liver index: a simple
and accurate predictor of colorectal adenoma in an average-risk
population. Dis Colon Rectum. 2018;61:36–42.
59. Rustagi T, Zarookian EI, Qasba O, et al. Chronic hepatitis C
as a risk factor for colorectal adenoma. Int J Colorectal Dis.
2014;29:75–80.
60. Yi SW, Ohrr H, Hong JS, et al. Agent orange exposure and prevalence of self-reported diseases in korean vietnam veterans. J Prev
Med Public Health. 2013;46:213–225.
61. Shaw E, Warkentin MT, McGregor SE, et al. Intake of dietary
fibre and lifetime non-steroidal anti-inflammatory drug (NSAID)
use and the incidence of colorectal polyps in a population
screened for colorectal cancer. J Epidemiol Community Health.
2017;71:961–969.
62. Wang L, Jacobs JP, Lagishetty V, et al. High-protein diet promotes sensitivity to cholecystokinin and shifts the cecal microbiome without altering brain inflammation in diet-induced obesity
in rats. Am J Physiol Regul Integr Comput Physiol. 2017. https: //
doi.org/10.1152/ajpregu001052017.
63. Wang LJJ, Lagishetty V, Yuan PQ, et al. Am J Physiol Regul
Integr Comput Physiol. 2017;313:R473–R486.
64. Li R, Yang J, Saffari A, et al. Ambient ultrafine particle ingestion
alters gut microbiota in association with increased atherogenic
lipid metabolites. Sci Rep. 2017;7:42906.
65. O’Brien MJ, Gibbons D. The adenoma-carcinoma sequence in
colorectal neoplasia. Surg Oncol Clin N Am. 1996;5:513–530.
66. Lakoff J, Paszat LF, Saskin R, et al. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol.
2008;6:1117–1121. (quiz 1064).
67. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators
for colonoscopy and the risk of interval cancer. N Engl J Med.
2010;362:1795–1803.
68. Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of
adenomas missed by optical colonoscopy. Ann Intern Med.
2004;141:352–359.
69. Rex DK. Maximizing detection of adenomas and cancers during
colonoscopy. Am J Gastroenterol. 2006;101:2866–2877.
70. Matsumoto T, Iida M, Kuwano Y, et al. Small nonpolypoid neoplastic lesions of the colon: endoscopic features with emphasis
on their progression. Gastrointest Endosc. 1995;41:135–140.
71. Brooker JC, Saunders BP, Shah SG, et al. Total colonic dye-spray
increases the detection of diminutive adenomas during routine
colonoscopy: a randomized controlled trial. Gastrointest Endosc.
2002;56:333–338.
72. Anderson JC, Butterly LF. Colonoscopy: quality indicators. Clin
Transl Gastroenterol. 2015;6:e77.
73. Rex DK, Kahi C, O’Brien M, et al. The American Society for
Gastrointestinal Endoscopy PIVI (Preservation and incorporation of valuable endoscopic innovations) on real-time endoscopic
assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc. 2011;73:419–422.
74. Hassan C, Pickhardt PJ, Rex DK. A resect and discard strategy
would improve cost-effectiveness of colorectal cancer screening.
Clin Gastroenterol Hepatol. 2010;8:865–869.

1135
75. Ignjatovic A, East JE, Suzuki N, et al. Optical diagnosis of
small colorectal polyps at routine colonoscopy (Detect InSpect
ChAracterise Resect and Discard; DISCARD trial): a prospective cohort study. Lancet Oncol. 2009;10:1171–1178.
76. Subramanian V, Mannath J, Hawkey CJ, et al. High definition
colonoscopy vs. standard video endoscopy for the detection of
colonic polyps: a meta-analysis. Endoscopy. 2011;43:499–505.
77. Kahi CJ, Anderson JC, Waxman I, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for
average-risk colorectal cancer screening. Am J Gastroenterol.
2010;105:1301–1307.
78. Leufkens AM, DeMarco DC, Rastogi A, et al. Effect of a
retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc.
2011;73:480–489.
79. Gralnek IM, Siersema PD, Halpern Z, et al. Standard forwardviewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial.
Lancet Oncol. 2014;15:353–360.
80. Floer M, Biecker E, Fitzlaff R, et al. Higher adenoma detection rates with endocuff-assisted colonoscopy—a randomized
controlled multicenter trial. PLoS ONE. 2014;9:e114267.
81. Dik VK, Gralnek IM, Segol O, et al. Multicenter, randomized,
tandem evaluation of EndoRings colonoscopy–results of the
CLEVER study. Endoscopy. 2015;47:1151–1158.
82. Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete mesocolic excision and
central ligation–technical notes and outcome. Colorectal Dis.
2009;11:354–364. (discussion 364-5).
83. Andreoni B, Chiappa A, Bertani E, et al. Surgical outcomes for
colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World
J Surg Oncol. 2007;5:73.
84. Campos FG, Calijuri-Hamra MC, Imperiale AR, et al. Locally
advanced colorectal cancer: results of surgical treatment and
prognostic factors. Arq Gastroenterol. 2011;48:270–275.
85. Mayo SC, Pulitano C, Marques H, et al. Surgical management
of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg. 2013;216:707–
716. (discussion 716-8).
86. Ruo L, Guillem JG. Surgical management of primary colorectal
cancer. Surg Oncol. 1998;7:153–163.
87. Yedibela S, Klein P, Feuchter K, et al. Surgical management of
pulmonary metastases from colorectal cancer in 153 patients.
Ann Surg Oncol. 2006;13:1538–1544.
88. Manfredi S, Benhamiche AM, Meny B, et al. Populationbased study of factors influencing occurrence and prognosis
of local recurrence after surgery for rectal cancer. Br J Surg.
2001;88:1221–1227.
89. Manfredi S, Bouvier AM, Lepage C, et al. Incidence and patterns of recurrence after resection for cure of colonic cancer
in a well defined population. Br J Surg. 2006;93:1115–1122.
90. Abulafi AM, Williams NS. Local recurrence of colorectal
cancer: the problem, mechanisms, management and adjuvant
therapy. Br J Surg. 1994;81:7–19.
91. Bouvet M, Hoffman RM. Glowing tumors make for better
detection and resection. Sci Transl Med. 2011;3:110fs10.
92. Metildi CA, Kaushal S, Luiken GA, et al. Fluorescently
labeled chimeric anti-CEA antibody improves detection and
resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Surg Oncol.
2014;109:451–458.
93. Nguyen QT, Tsien RY. Fluorescence-guided surgery with live
molecular navigation–a new cutting edge. Nat Rev Cancer.
2013;13:653–662.

13

1136
94. Vahrmeijer AL, Hutteman M, van der Vorst JR, et al. Imageguided cancer surgery using near-infrared fluorescence. Nat
Rev Clin Oncol. 2013;10:507–518.
95. DeLong JC, Hoffman RM, Bouvet M. Current status and future
perspectives of fluorescence-guided surgery for cancer. Expert
Rev Anticancer Ther. 2016;16:71–81.
96. Hiroshima Y, Lwin TM, Murakami T, et al. Effective fluorescence-guided surgery of liver metastasis using a fluorescent
anti-CEA antibody. J Surg Oncol. 2016;114:951–958.
97. Hiroshima Y, Maawy A, Metildi CA, et al. Successful fluorescence-guided surgery on human colon cancer patient-derived
orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. J
Laparoendosc Adv Surg Tech A. 2014;24:241–247.
98. Kaushal S, McElroy MK, Luiken GA, et al. Fluorophoreconjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg.
2008;12:1938–1950.
99. Metildi CA, Kaushal S, Pu M, et al. Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves
surgical resection and increases survival in orthotopic
mouse models of human pancreatic cancer. Ann Surg Oncol.
2014;21:1405–1411.
100. Metildi CA, Kaushal S, Snyder CS, et al. Fluorescence-guided
surgery of human colon cancer increases complete resection
resulting in cures in an orthotopic nude mouse model. J Surg
Res. 2013;179:87–93.
101. Hiroshima Y, Lwin TM, Murakami T, et al. Effective fluorescence-guided surgery of liver metastasis using a fluorescent antiCEA antibody. J Surg Oncol. 2016;114:951–958.
102. Yazaki PJ, Sherman MA, Shively JE, et al. Humanization of the
anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel. 2004;17:481–489.
103. Gutowski M, Framery B, Boonstra MC, et al. SGM-101: An
innovative near-infrared dye-antibody conjugate that targets CEA
for fluorescence-guided surgery. Surg Oncol. 2017;26:153–162.
104. Park JY, Murakami T, Lee JY, et al. Fluorescent-antibody targeting of insulin-like growth factor-1 receptor visualizes metastatic
human colon cancer in orthotopic mouse models. PLoS ONE.
2016;11:e0146504.
105. Yano S, Takehara K, Miwa S, et al. Improved resection and
outcome of colon-cancer liver metastasis with fluorescenceguided surgery using in situ GFP labeling with a telomerasedependent adenovirus in an orthotopic mouse model. PLoS ONE.
2016;11:e0148760.
106. Metildi CA, Felsen CN, Savariar EN, et al. Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases
and recurrence in orthotopic mouse models. Ann Surg Oncol.
2015;22:2082–2087.
107. Jafari MD, Wexner SD, Martz JE, et al. Perfusion assessment in
laparoscopic left-sided/anterior resection (PILLAR II): a multiinstitutional study. J Am Coll Surg. 2015;220(82–92):e1.
108. Tipirneni KE, Warram JM, Moore LS, et al. Oncologic procedures amenable to fluorescence-guided surgery. Ann Surg.
2017;266:36–47.
109. Inoue Y, Kusunoki M. Advances and directions in chemotherapy
using implantable port systems for colorectal cancer: a historical
review. Surg Today. 2014;44:1406–1414.
110. Ahmed S, Johnson K, Ahmed O, et al. Advances in the management of colorectal cancer: from biology to treatment. Int J
Colorectal Dis. 2014;29:1031–1042.
111. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic
advances in the treatment of colorectal cancer. Annu Rev Med.
2015;66:83–95.

13

Digestive Diseases and Sciences (2018) 63:1123–1138
112. Xiong M, Lei Q, You X, et al. Mannosylated liposomes
improve therapeutic effects of paclitaxel in colon cancer models. J Microencapsul. 2017;34:513–521.
113. Patras L, Sylvester B, Luput L, et al. Liposomal prednisolone
phosphate potentiates the antitumor activity of liposomal
5-fluorouracil in C26 murine colon carcinoma in vivo. Cancer
Biol Ther. 2017;18:616–626.
114. Slattery ML, Herrick JS, Stevens JR, et al. An assessment of
database-validated microRNA target genes in normal colonic
mucosa: implications for pathway analysis. Cancer Inform.
2017;16:1176935117716405.
115. Yao J, Zhang P, Li J, et al. MicroRNA-215 acts as a tumor
suppressor in breast cancer by targeting AKT serine/threonine
kinase 1. Oncol Lett. 2017;14:1097–1104.
116. Zheng J, He S, Qi J, et al. Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and
in vivo. Int J Oncol. 2017;51:478–488.
117. Villalba M, Evans SR, Vidal-Vanaclocha F, et al. Role of TGFbeta in metastatic colon cancer: it is finally time for targeted
therapy. Cell Tissue Res. 2017;370:29–39.
118. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor
cells as regulators of the immune system. Nat Rev Immunol.
2009;9:162–174.
119. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells.
Adv Exp Med Biol. 2007;601:213–223.
120. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells
in human cancer. Cancer J. 2010;16:348–353.
121. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of
antigen is a novel mechanism of CD8 + T cell tolerance in cancer. Nat Med. 2007;13:828–835.
122. Chung KY, Gore I, Fong L, et al. Phase II study of the anticytotoxic T-lymphocyte-associated antigen 4 monoclonal
antibody, tremelimumab, in patients with refractory metastatic
colorectal cancer. J Clin Oncol. 2010;28:3485–3490.
123. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of
anti-PD-L1 antibody in patients with advanced cancer. N Engl
J Med. 2012;366:2455–2465.
124. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J
Med. 2012;366:2443–2454.
125. Nagaraj S, Pisarev V, Kinarsky L, et al. Dendritic cell-based
full-length survivin vaccine in treatment of experimental
tumors. J Immunother. 2007;30:169–179.
126. Koido S, Ohkusa T, Homma S, et al. Immunotherapy for colorectal cancer. World J Gastroenterol. 2013;19:8531–8542.
127. Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immunotherapy. Discov Med. 2013;15:301–308.
128. Signorini L, Delbue S, Ferrante P, et al. Review on the immunotherapy strategies against metastatic colorectal carcinoma.
Immunotherapy. 2016;8:1245–1261.
129. Tran E, Robbins PF, Lu YC, et al. T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med.
2016;375:2255–2262.
130. Le DT, Uram JN, Wang H, et al. PD-1 blockade in
tumors with mismatch-repair deficiency. N Engl J Med.
2015;372:2509–2520.
131. Millner LM, Strotman LN. The future of precision medicine in
oncology. Clin Lab Med. 2016;36:557–573.
132. Duzkale H, Shen J, McLaughlin H, et al. A systematic approach
to assessing the clinical significance of genetic variants. Clin
Genet. 2013;84:453–463.
133. Meehan RS, Chen AP. New treatment option for ovarian cancer:
PARP inhibitors. Gynecol Oncol Res Pract. 2016;3:3.
134. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated
hereditary breast and ovarian cancer. In: Pagon RA, Adam MP,

Digestive Diseases and Sciences (2018) 63:1123–1138

135.
136.
137.
138.
139.
140.
141.

142.
143.
144.
145.
146.
147.
148.
149.

150.

Ardinger HH, et al., eds. GeneReviews(R). Seattle, WA: University of Washington; 1993.
Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, Adam
MP, Ardinger HH, et al., eds. GeneReviews(R). Seattle, WA: University of Washington; 1993.
Dong L, Wang W, Li A, et al. Clinical next generation
sequencing for precision medicine in cancer. Curr Genomics.
2015;16:253–263.
Mak IW, Evaniew N, Ghert M. Lost in translation: animal
models and clinical trials in cancer treatment. Am J Transl Res.
2014;6:114–118.
Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell.
2015;163:39–53.
Pereira JF, Awatade NT, Loureiro CA, et al. The third dimension:
new developments in cell culture models for colorectal research.
Cell Mol Life Sci. 2016;73:3971–3989.
Huh D, Kim HJ, Fraser JP, et al. Microfabrication of human
organs-on-chips. Nat Protoc. 2013;8:2135–2157.
Nair R, Padhee S, Das T, et al. Three- and four-dimensional
spheroid and fiss tumoroid cultures: platforms for drug discovery
and development, and translational research. Crit Rev Ther Drug
Carr Syst. 2017;34(3):185–208.
Yoon YS, Kim JC. Recent applications of chemosensitivity
tests for colorectal cancer treatment. World J Gastroenterol.
2014;20:16398–16408.
Hur H, Kim NK, Kim HG, et al. Adenosine triphosphate-based
chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. Br J Cancer. 2012;106:53–60.
Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst. 1990;82:582–588.
Mechetner E, Brunner N, Parker RJ. In vitro drug responses in
primary and metastatic colorectal cancers. Scand J Gastroenterol. 2011;46:70–78.
Fan CW, Fan HA, Hsu SH, et al. An in vitro short time-high dose
drug exposure assay for predicting 5FU-resistance of colorectal
cancer. Cancer Lett. 2004;214:181–188.
Das T, Nair RR, Green R, et al. Actinomycin D down-regulates
SOX2 expression and induces death in breast cancer stem cells.
Anticancer Res. 2017;37:1655–1663.
Girard YK, Wang C, Ravi S, et al. A 3D fibrous scaffold inducing
tumoroids: a platform for anticancer drug development. PLoS
ONE. 2013;8:e75345.
Gluck S, de Snoo F, Peeters J, et al. Molecular subtyping of
early-stage breast cancer identifies a group of patients who do
not benefit from neoadjuvant chemotherapy. Breast Cancer Res
Treat. 2013;139:759–767.
Gluck S, McKenna EF Jr, Royce M. XeNA: capecitabine plus
docetaxel, with or without trastuzumab, as preoperative therapy
for early breast cancer. Int J Med Sci. 2008;5:341–346.

1137
151. Stachelscheid H, Wulf-Goldenberg A, Eckert K, et al. Teratoma formation of human embryonic stem cells in three-dimensional perfusion culture bioreactors. J Tissue Eng Regen Med.
2013;7:729–741.
152. Chen J, Xia Q, Jiang B, et al. Prognostic value of cancer stem
cell marker ALDH1 expression in colorectal cancer: a systematic
review and meta-analysis. PLoS ONE. 2015;10:e0145164.
153. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance
of circulating tumor cells, including cancer stem-like cells,
in peripheral blood for recurrence and prognosis in patients
with Dukes’ stage B and C colorectal cancer. J Clin Oncol.
2011;29:1547–1555.
154. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and
cancer stem cells. Nature. 2001;414:105–111.
155. Scatena R, Bottoni P, Pontoglio A, et al. Cancer stem cells: the
development of new cancer therapeutics. Expert Opin Biol Ther.
2011;11:875–892.
156. Carmody L, Germain A, Morgan B, et al. Identification of a
selective small-molecule inhibitor of breast cancer stem cells—
probe 3. In: Probe Reports from the NIH Molecular Libraries
Program. Bethesda (MD); 2010.
157. Carmody L, Germain A, Morgan B, et al. Identification of a
selective small-molecule inhibitor of breast cancer stem cells—
probe 1. In: Probe Reports from the NIH Molecular Libraries
Program. Bethesda, MD; 2010.
158. Carmody LC, Germain A, Morgan B, et al. Identification of
a Selective Small-Molecule Inhibitor of Breast Cancer Stem
Cells—Probe 2. In: Probe Reports from the NIH Molecular
Libraries Program. Bethesda, MD; 2010.
159. Carmody LC, Germain AR, VerPlank L, et al. Phenotypic highthroughput screening elucidates target pathway in breast cancer
stem cell-like cells. J Biomol Screen. 2012;17:1204–1210.
160. Germain AR, Carmody LC, Nag PP, et al. Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013;23:1834–1838.
161. Hirano K, Sasaki N, Ichimiya T, et al. 3-O-sulfated heparan sulfate recognized by the antibody HS4C3 contributes [corrected] to
the differentiation of mouse embryonic stem cells via fas signaling. PLoS ONE. 2012;7:e43440.
162. Johnson CE, Crawford BE, Stavridis M, et al. Essential alterations of heparan sulfate during the differentiation of embryonic
stem cells to Sox1-enhanced green fluorescent protein-expressing
neural progenitor cells. Stem Cells. 2007;25:1913–1923.
163. Nairn AV, Kinoshita-Toyoda A, Toyoda H, et al. Glycomics of
proteoglycan biosynthesis in murine embryonic stem cell differentiation. J Proteome Res. 2007;6:4374–4387.

Affiliations

Shyam S. Mohapatra1,2,3,4 · Surinder K. Batra1,5 · Srinivas Bharadwaj3 · Michael Bouvet1,6,7 · Bard Cosman6,7 ·
Ajay Goel1,8,9 · Wilma Jogunoori10,11 · Michael J. Kelley1,12,13 · Lopa Mishra1,10,11 · Bibhuti Mishra10,11 ·
Subhra Mohapatra1,2,14 · Bhaumik Patel1,15 · Joseph R. Pisegna1,16,17 · Jean‑Pierre Raufman1,18 · Shuyun Rao10,11 ·
Hemant Roy19 · Maren Scheuner1,16,17 · Satish Singh1,20 · Gitanjali Vidyarthi2,3 · Jon White10,11
Surinder K. Batra
sbatra@unmc.edu

Bard Cosman
Bard.Cosman@va.gov

Michael Bouvet
mbouvet@ucsd.edu

Ajay Goel
Ajay.Goel@BSWHealth.org

13

1138

Digestive Diseases and Sciences (2018) 63:1123–1138

Michael J. Kelley
kelleym@duke.edu

7

Department of Surgery, University of California San Diego
Moores Cancer Center, San Diego, CA, USA

Lopa Mishra
lmishra@email.gwu.edu

8

Subhra Mohapatra
smohapa2@health.usf.edu

Center for Gastrointestinal Research, Center for Translational
Genomics and Oncology, Baylor Scott & White Research
Institute, Dallas, TX, USA

9

Bhaumik Patel
Bhaumik.Patel@va.gov

Charles A. Sammons Cancer Center, Baylor University,
Dallas, TX, USA

10

Washington DC VA Medical Center, Washington, DC, USA

Joseph R. Pisegna
Joseph.Pisegna@va.gov

11

Department of Surgery, Center for Translational Medicine,
George Washington University, Washington, DC, USA

Jean‑Pierre Raufman
jraufman@som.umaryland.edu

12

Hemant Roy
hkroy@bu.edu

National Oncology Program Office, Specialty Care Services,
Department of Veterans Affairs, Durham VA Medical Center,
Durham, NC, USA

13

Maren Scheuner
Maren.Scheuner@va.gov

Department of Medicine, Duke University Medical Center,
Durham, NC, USA

14

Satish Singh
Satish.Singh@va.gov

Department of Molecular Medicine, Morsani College
of Medicine, University of South Florida, Tampa, FL, USA

15

Hunter Holmes McGuire VA Medical Center and Department
of Internal Medicine, Virginia Commonwealth University
School of Medicine, Richmond, VA, USA

16

Division of Gastroenterology and Human Genetics, VA
Greater Los Angeles Healthcare System, Los Angeles, CA,
USA

Gitanjali Vidyarthi
Gitanjali.Vidyarthi@va.gov
1

Department of Veterans Affairs Colorectal Cancer Cellgenomics Consortium [VA4C], Tampa, FL, USA

2

James A. Haley Veterans Hospital, Tampa, FL, USA

17

3

Division of Translational Medicine, Department of Internal
Medicine, Morsani College of Medicine, University of South
Florida, Tampa, FL, USA

Department of Medicine, David Geffen School of Medicine
at UCLA, Los Angeles, CA, USA

18

College of Pharmacy Graduate Programs, University
of South Florida, Tampa, FL, USA

VA Maryland Health Care System, Department of Medicine,
University of Maryland School of Medicine, Baltimore, MD,
USA

19

Department of Medicine, Boston University School
of Medicine, Boston, MA, USA

20

VA Boston Healthcare System and Department of Medicine,
Boston University School of Medicine, Boston, MA, USA

4

5

6

Department of Biochemistry and Molecular Biology,
Fred and Pamela Buffett Cancer Center, Eppley Institute
for Research in Cancer, University of Nebraska Medical
Center, Omaha, NE, USA
VA San Diego Healthcare System, San Diego, CA, USA

13

